NICE okays regular NHS funding for Novartis' breast cancer d...

NICE has recommended moving Novartis’ Kisqali (ribociclib) from interim funding arrangements to regular NHS reimbursement for certain previously treated breast cancer patients.

Novartis CEO thinks 2nd health lockdown unlikely, as Q3 sale...

Novartis’ pharmaceutical sales recovered in the third quarter of this year after an earlier COVID-19 decline, as new drugs like gene therapy Zolgensma gathered pace.  

NICE changes its mind on Novartis’ Kisqali for breast cancer